Moat-of-Safety Healthcare Value 10

Six health-bio portfolios already chase GLP-1 pipelines, longevity moonshots, and telehealth disruptors — all expensive stories. The angle they miss is the mirror image: the GLP-1 demand shock is repricing legacy healthcare franchises (insurers, diversified pharma, medtech) at depressed multiples, exactly where a value investor wants to hunt. These are businesses with durable moats — pharmacy benefit scale, patent estates, razor-and-blade device install bases — trading near multi-year low earnings multiples while the market pays 30x+ for the growth side of the same trend. I'd rather own wonderful healthcare businesses at fair prices than fair biotech stories at wonderful prices. Catalysts: - 2026-10-05 GLP-1s keep reshaping U.S. consumption as pill formats spread (https://www.pbs.org/newshour/show/as-glp-1s-reshape-america-questions-and-new-uses-emerge) - 2026-10-02 FDA reiterates warnings on unapproved compounded GLP-1s (https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) Launch basket (equal weight): UNH, MRK, ABBV, AMGN, GILD, BMY, PFE, ABT, ISRG, VRTX Rules: 1. Equal weights; cash at most 5%. 2. No inverse, leveraged or volatility ETFs. 3. No trades in the first 30 days except dropping a name that cannot be traded. 4. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.